DOCSLIB.ORG

Management of Skin and Soft Tissue Infections (SSTI) Signs and Symptoms of Abscess And/Or Cellulitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Skin and Soft Tissue Infections (SSTI) Signs and Symptoms of Abscess And/Or Cellulitis Management of Skin and Soft Tissue Infections (SSTI) Signs and Symptoms of Abscess and/or Cellulitis Evaluate for Complicating Factors1,2 s/sx system infection: WBC > 12,000 or < 4000; T > Abscess difficult to drain (face, hand, perineum) 38.0 or <36oC ; HR > 90; RR > 24 Abscess > 5 cm in diameter immunosuppressed Multiple lesions End-stage organ failure Bites Diabetes Water exposure Extensive surrounding cellulitis History of trauma, purulent cellulitis, recurrent Advanced age ( > 65 years of age) MRSA infection, MRSA exposure Obesity (BMI > 30) No response to treatment after 48 hours 0-1 complicating factors2 2 or more complicating factors2 Purulent lesion or COMPLICATED concern for abscess? Cutaneous abscess and/or cellulitis no yes 1,2 Evaluate need for hospitalization Severe SSTI with one or more of the following: SIMPLE CELLULITIS SIMPLE ABSCESS Failed outpatient therapy ( > 48 hours) and patient (painful, tender, fluctuant requires hospital support (No evidence of abscess, bites, red nodules) water exposure, diabetic foot Severe SSTI in immunocompromised patients (transplant ulcer, or recent surgery) patients, diabetes, chemotherapy, end-stage organ Extending dysfunction, etc.) cellulitis? Necrotizing fasciitis concerns (Consider CT, surgical no yes consult) Abscess of face, hand or perineum (difficult to drain areas) Treat abscess Treat abscess + Severe sepsis not responding to fluids Treat simple ( < 5 cm) cellulitis Septic shock cellulitis--> (a) --> I & D + (a) --> I & D only ANY of NONE of the above the above Hospital Admission ED or Infusion Center Observation or Follow-up • Blood cultures x2 • Blood cultures x2 If complicating factor (from list above), recommend • ASO titer • Culture of drainage close observation for clinical decline (inpatient or • MRSA mol amp (nares) or exudate prior to outpatient) • Culture of drainage or antibiotics If NO complicating factors, 48-hr follow-up with ED or exudate prior to • PO or IV antibiotics PCP antibiotics in ED or infusion If no improvement, start antibiotics based on • Treatment based on center risk/presentation –> see algorithm (a) and consider adding algorithms (f) - (i) See algorithm (b) (see pages 2-5) or • MD assessment of gram-negative or MRSA coverage if initial therapy has sepsis bundle response after 48- failed (d) 72 hours TREATMENT ALGORITHM: SKIN & SOFT TISSUE INFECTIONS (SSTI) (Options are listed in order of preference) (a) UNCOMPLICATED CELLULITIS/ABSCESS: Outpatient Treatment1 CELLULITIS, NO MRSA RISK CELLULITIS with MRSA RISK ABSCESS + CELLULITIS • Cephalexin 500mg po QID* • Cephalexin 500mg po QID* + • TMP/SMX DS 1-2 tabs BID* • Dicloxacillin 250mg po QID TMP/SMX DS 1-2 tabs BID* • Doxycycline 100mg po BID • Clindamycin 300-450mg po QID • Cephalexin 500mg po QID* + (for > 65 y.o. and/or decreased RF) (use for severe PCN allergy) Doxycycline 100mg po BID • Clindamycin 300-450mg po QID Duration of therapy1 = 5 days for (for > 65 y.o .and/or decreased RF) For added Strep coverage: uncomplicated Cellulitis or abscess, however • Clindamycin 300-450mg po QID • Consider adding cephalexin (with treatment may be extended if not improved1 (use for severe PCN allergy) doxycycline or TMP/SMX) 3 Non-purulent Cellulitis Microbiology : MRSA Risk Factors5: Oral options for higher blood levels: 73% B-hemolytic Strep • Penetrating trauma • Linezolid **600mg po BID or 27% not identifiable • MRSA colonization • Tedizolid** 200mg po daily • [Cost may be a consideration with these 2 4 IV Drug abusers Purulent Cellulitis Microbiology : • SIRS options, in addition to interactions with 59% MRSA 3% B-hem Strep 9% unknown • Failure to respond to serotonergic agents (linezolid) and possible 17% MSSA 4% other Strep 8% other Beta-lactam therapy myelosuppressive effects] For simple Abscess < 5 cm: I & D only (b) COMPLICATED CELLULITIS +/- ABSCESS: Treatment at ED or INFUSION CENTER Oral antibiotics IV Therapy: Non-Purulent Cellulitis IV Therapy: Purulent Cellulitis • Cephalexin 500mg po QID* + • Ceftriaxone 1-2g IV q24h • Vancomycin 20mg/kg load f/b TMP/SMX DS 1-2 tabs BID* ADD if MRSA RISK: (see risk factors above) Pharmacy consult • Cephalexin 500mg po QID* + -TMP/SMX DS 1-2 tabs BID* or Doxycycline 100mg po BID -Doxycycline 100mg po BID (for > 65 y.o .and/or decreased RF) (for > 65 y.o. and/or decreased RF) 1 • Clindamycin 300-450mg po QID Duration of Therapy =: 5-10 days for (use for severe PCN allergy) Complicated Cellulitis/Abscess, based on response (c) BITE INFECTIONS Criteria for antibiotic therapy Empiric Therapy: Oral/IV options Cat Scratch Disease Prophylactic antibiotic treatment x 3-5 days • Amoxicillin-clavulanate 875mg Azithromycin: if: BID* or • Patients >45 kg: 500mg • Immunocompromised or asplenic • Ampicillin/sulbactam 3g IV q6h* x 1, then 250mg/day x 4 • Advanced liver disease • Cefuroxime* + metronidazole • Patients <45kg: 10mg/kg • Edema in affected area • Doxycycline 100mg po BID x 1, then 5mg/kg/d x 4 • Mod-severe injuries, especially to the • TMP-SMX* + metronidazole hand or face For treatment of tenosynovitis or abscess Bacillary angiomatosis: • Penetration of periosteum or joint development, surgical debridement and a Erythromycin 500mg qid or capsule longer duration of therapy (7-14 days) may Doxycycline 100mg bid Consider HIV, Hepatitis B or C risks with be required Duration: 2 weeks to 2 months human bites Also consider addition of: • Post-exposure prophylaxis for rabies • TDAP or Tetanus toxoid if not up to date *requires dose adjustment for decreased renal function (See page 5) **ID/ASP review required † ID restricted antibiotic TREATMENT ALGORITHM: SKIN & SOFT TISSUE INFECTIONS (SSTI) (Options are listed in order of preference) (d) FACIAL SKIN & SOFT TISSUE INFECTION Deep Head & Neck Soft Tissue Infections Facial Cellulitis Odontogenic source originating from skin/sinuses Pathogens: S.aureus, Strep sp. , Pathogens: Treatment: anaerobes Common: S. aureus, S. pneumoniae and other • Amoxicillin-clavulanate 875mg Strep sp., anaerobes TID* Treatment: Uncommon: H. influenza, A. hydrophila, • Ampicillin/sulbactam 3g IV • Cephalexin 500mg po QID* + E.corrodens, Mucorales, Aspergillus q6h* TMP/SMX DS 1-2 tabs BID* • Cefuroxime 500mg BID* + • Cephalexin 500mg po QID* + Treatment: Clindamycin 300mg QID Doxycycline 100mg po BID • Vancomycin: 20mg/kg load, f/b Pharmacy consult • Cefuroxime 750-1.5g IV q8h* + (for > 65 y.o .and/or decreased RF) + Clindamycin 600-900mg IV q8h Ceftriaxone 1-2g IV q24h or (for severe penicillin allergy) • Clindamycin 300-450mg po QID Amp-sulbactam 3g IV q6h (use for severe PCN allergy) (e) RECURRENT CELLULITIS/ABSCESS: ADJUNCTIVE THERAPIES MRSA Resistance to Vancomycin: Non-purulent Cellulitis Recurrent Abscess Although our antibiograms report Treat pre-disposing factors: • Drain & culture • Tinea pedis-> Clotrimazole 1% cream bid • 5-10 day course of appropriate 100% S.aureus vancomycin • Edema antibiotic susceptibility, with 5% of SHC • Venous insufficiency • Search for local causes: pilonidal isolates (n=6181) having an • Underlying cutaneous disorders, i.e. cyst, hidradenitis suppurativa, or MIC=2.0, alternatives may be eczema foreign material considered for infections that do • Obesity • Consider 5-day decolonization: not respond to Vancomycin: • Prophylactic antibiotics (penicillin or intranasal mupirocin, daily erythromycin BID) if pre-disposing factors chlorhexidine washes, daily • Linezolid** 600mg po/IV decontamination of sheets, towels persist and >3-4 episodes/year BID & clothes • Tedizolid** 200mg po/IV Other notes: -Duration of Therapy for Complicated Cellulitis/Abscess: 5-10 days based on response daily -Erysipelas may require 7-10 days of treatment • Daptomycin † 6mg/kg IV -Pyomyositis should be treated as complicated purulent cellulitis with recommended duration of q24h* therapy extended to 2-3 weeks. • Ceftaroline † 600mg IV -Minocycline may be substituted for Doxycycline, to avoid photosensitivity (same dose) -The addition of Probiotic therapy is recommended with antimicrobial courses for prevention of q12h* C.difficile infections associated with antimicrobial therapy *requires dose adjustment for decreased renal function (See page 5) **ID/ASP review required † ID restricted antibiotic TREATMENT ALGORITHM: SKIN & SOFT TISSUE INFECTIONS (SSTI) (Options are listed in order of preference) (f) COMPLICATED NON-PURULENT CELLULITIS: Treatment for Hospital Admission If NON-Sepsis or ICU NON-Sepsis w/MRSA Risk Severe Sepsis / ICU admission • Cefazolin 1-2g IV q8h* • Cefazolin 1-2g IV q8h* + • Vancomycin per Pharmacy + or Vancomycin 20mg/kg load f/b Clindamycin 900mg IV q8h + • Ceftriaxone 1-2g IV q24h Pharmacy consult or Piperacillin-tazo 4.5g IV q8h* (substitute for broader gram- • Clindamycin 600-900mg IV q8h negative coverage - see risk factors • Vancomycin + Clindamycin IV + below) • Substitute for broader gram- Meropenem** 1g IV q8h* negative coverage if needed: (for severe penicillin allergy) Ceftriaxone 1-2g IV q24h (see risk factors below) Please note: Gram Negative Rod Risk Factors: 1 -Duration of Therapy for Complicated Cellulitis/Abscess: 5-10 days based on response • Neutropenia [see (f) page 3] -Dosing: Higher listed doses of cefazolin, clindamycin, cefuroxime, nafcillin and ceftriaxone • HIV or severely are recommended for patients >100kg immunocompromised -De-escalate IV to oral therapy after 48-72 hours, or as patient responds/improves • Trauma in aquatic environment -Diabetic Foot Infections are not covered in this treatment algorithm. Please refer to the • 8 Burns IDSA guideline
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • Cefoxitin Versus Piperacillin– Tazobactam As Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy: Protocol for a Randomised Controlled Trial
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2020-048398 on 4 March 2021. Downloaded from Cefoxitin versus piperacillin– tazobactam as surgical antibiotic prophylaxis in patients undergoing pancreatoduodenectomy: protocol for a randomised controlled trial Nicole M Nevarez ,1 Brian C Brajcich,2 Jason Liu,2,3 Ryan Ellis,2 Clifford Y Ko,2 Henry A Pitt,4 Michael I D'Angelica,5 Adam C Yopp1 To cite: Nevarez NM, ABSTRACT Strengths and limitations of this study Brajcich BC, Liu J, et al. Introduction Although antibiotic prophylaxis is Cefoxitin versus piperacillin– established in reducing postoperative surgical site tazobactam as surgical ► A major strength of this study is the multi- infections (SSIs), the optimal antibiotic for prophylaxis in antibiotic prophylaxis institutional, double- arm, randomised controlled in patients undergoing pancreatoduodenectomy (PD) remains unclear. The study trial design. objective is to evaluate if administration of piperacillin– pancreatoduodenectomy: ► A limitation of this study is that all perioperative care protocol for a randomised tazobactam as antibiotic prophylaxis results in decreased is at the discretion of the operating surgeon and is controlled trial. BMJ Open 30- day SSI rate compared with cefoxitin in patients not standardised. 2021;11:e048398. doi:10.1136/ undergoing elective PD. ► All data will be collected through the American bmjopen-2020-048398 Methods and analysis This study will be a multi- College of Surgeons National Surgical Quality ► Prepublication history for institution, double- arm, non- blinded randomised controlled Improvement Program, which is a strength for its this paper is available online. superiority trial. Adults ≥18 years consented to undergo PD ease of use but a limitation due to the variety of data To view these files, please visit for all indications who present to institutions participating included.
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Melioidosis: an Emerging Infectious Disease
    Review Article www.jpgmonline.com Melioidosis: An emerging infectious disease Raja NS, Ahmed MZ,* Singh NN** Department of Medical ABSTRACT Microbiology, University of Malaya Medical Center, Kuala Lumpur, Infectious diseases account for a third of all the deaths in the developing world. Achievements in understanding Malaysia, *St. the basic microbiology, pathogenesis, host defenses and expanded epidemiology of infectious diseases have Bartholomew’s Hospital, resulted in better management and reduced mortality. However, an emerging infectious disease, melioidosis, West Smithfield, London, is becoming endemic in the tropical regions of the world and is spreading to non-endemic areas. This article UK and **School of highlights the current understanding of melioidosis including advances in diagnosis, treatment and prevention. Biosciences, Cardiff Better understanding of melioidosis is essential, as it is life-threatening and if untreated, patients can succumb University, Cardiff, UK to it. Our sources include a literature review, information from international consensus meetings on melioidosis Correspondence: and ongoing discussions within the medical and scientific community. N. S. Raja, E-mail: [email protected] Received : 21-2-2005 Review completed : 20-3-2005 Accepted : 30-5-2005 PubMed ID : 16006713 KEY WORDS: Melioidosis, Burkholderia pseudomallei, Infection J Postgrad Med 2005;51:140-5 he name melioidosis [also known as Whitmore dis- in returning travellers to Europe from endemic areas.[14] The T ease] is taken from the Greek word ‘melis’ meaning geographic area of the prevalence of the organism is bound to distemper of asses and ‘eidos’ meaning resembles glanders. increase as the awareness increases. Melioidosis is a zoonotic disease caused by Pseudomonas pseudomallei [now known as Burkholderia pseudomallei], a B.
    [Show full text]
  • Hawaii State Department of Health Tetanus Factsheet
    TETANUS ABOUT THIS DISEASE Tetanus is an infection caused by a bacterium called Clostridium tetani. Spores of tetanus bacteria are everywhere in the environment, including soil, dust, and manure. These spores develop into bacteria when they enter the body through breaks in the skin, usually through injuries from contaminated objects. Clostridium tetani produce a toxin (poison) that causes painful muscle contractions. Tetanus is often called “lockjaw” because the first sign is most commonly spasms of the jaw muscles. Tetanus can lead to serious health problems, including being unable to open the mouth and having trouble swallowing and breathing, possibly leading to death (10% to 20% of cases). Tetanus is uncommon in the United States, with an average of 30 reported cases each year. Nearly all cases of tetanus in the U.S. are among people who have never received a tetanus vaccine, or adults who don’t stay up to date on their 10-year booster shots. SIGNS AND SYMPTOMS Symptoms of tetanus include: • Jaw cramping • Sudden, involuntary muscle tightening (muscle spasms) – often in the stomach • Painful muscle stiffness all over the body • Trouble swallowing • Jerking or staring (seizures) • Headache • Fever and sweating • Changes in blood pressure and a fast heart rate. Serious health problems that can happen because of tetanus include: • Laryngospasm (uncontrolled/involuntary tightening of the vocal cords) • Fractures (broken bones) • Hospital-acquired infections (Infections caught by a patient during a hospital stay) • Pulmonary embolism (blockage of the main artery of the lung or one of its branches by a blood clot that has travelled from elsewhere in the body through the bloodstream) • Aspiration pneumonia (lung infection that develops by breathing in foreign materials) • Breathing difficulty, possibly leading to death (1 to 2 in 10 cases are fatal) TRANSMISSION Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person.
    [Show full text]
  • Safety and Immunogenicity of Capsular Polysaccharide–Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and Ib
    142 Safety and Immunogenicity of Capsular Polysaccharide±Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and Ib Carol J. Baker, Lawrence C. Paoletti, Section of Infectious Diseases, Departments of Pediatrics and of Michael R. Wessels, Hilde-Kari Guttormsen, Microbiology and Immunology, Baylor College of Medicine, Houston, Marcia A. Rench, Melissa E. Hickman, Texas; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Department of Microbiology and Molecular and Dennis L. Kasper Genetics, Harvard Medical School, Boston, Massachusetts About 40% of invasive group B streptococcal (GBS) isolates are capsular polysaccharide Downloaded from https://academic.oup.com/jid/article/179/1/142/877598 by guest on 01 October 2021 (CPS) types Ia or Ib. Because infant and maternal GBS infections may be preventable by maternal vaccination, individual GBS CPS have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced immunogenicity. Immunogenicity in rabbits and protective capacity in mice of a series of type Ia- and Ib-TT conjugates increased with the degree of polysaccharide-to-protein cross-linking. In total, 190 healthy, nonpregnant women aged 18±40 years were randomized in four trials to receive Ia- or Ib-TT conjugate (dose range, 3.75±63 mg of CPS component), uncoupled Ia or Ib CPS, or saline. All vaccines were well-tolerated. CPS-speci®c IgG serum concentrations peaked 4±8 weeks after vaccination and were signif- icantly higher in recipients of conjugated than of uncoupled CPS. Immune responses to the conjugates were dose-dependent and correlated in vitro with opsonophagocytosis. These re- sults support inclusion of Ia- and Ib-TT conjugates when formulating a multivalent GBS vaccine.
    [Show full text]
  • Cutaneous Manifestations of HIV Infection Carrie L
    Chapter Title Cutaneous Manifestations of HIV Infection Carrie L. Kovarik, MD Addy Kekitiinwa, MB, ChB Heidi Schwarzwald, MD, MPH Objectives Table 1. Cutaneous manifestations of HIV 1. Review the most common cutaneous Cause Manifestations manifestations of human immunodeficiency Neoplasia Kaposi sarcoma virus (HIV) infection. Lymphoma 2. Describe the methods of diagnosis and treatment Squamous cell carcinoma for each cutaneous disease. Infectious Herpes zoster Herpes simplex virus infections Superficial fungal infections Key Points Angular cheilitis 1. Cutaneous lesions are often the first Chancroid manifestation of HIV noted by patients and Cryptococcus Histoplasmosis health professionals. Human papillomavirus (verruca vulgaris, 2. Cutaneous lesions occur frequently in both adults verruca plana, condyloma) and children infected with HIV. Impetigo 3. Diagnosis of several mucocutaneous diseases Lymphogranuloma venereum in the setting of HIV will allow appropriate Molluscum contagiosum treatment and prevention of complications. Syphilis Furunculosis 4. Prompt diagnosis and treatment of cutaneous Folliculitis manifestations can prevent complications and Pyomyositis improve quality of life for HIV-infected persons. Other Pruritic papular eruption Seborrheic dermatitis Overview Drug eruption Vasculitis Many people with human immunodeficiency virus Psoriasis (HIV) infection develop cutaneous lesions. The risk of Hyperpigmentation developing cutaneous manifestations increases with Photodermatitis disease progression. As immunosuppression increases, Atopic Dermatitis patients may develop multiple skin diseases at once, Hair changes atypical-appearing skin lesions, or diseases that are refractory to standard treatment. Skin conditions that have been associated with HIV infection are listed in Clinical staging is useful in the initial assessment of a Table 1. patient, at the time the patient enters into long-term HIV care, and for monitoring a patient’s disease progression.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Severe Sepsis and Septic Shock Antibiotic Guide
    Stanford Health Issue Date: 05/2017 Stanford Antimicrobial Safety and Sustainability Program Severe Sepsis and Septic Shock Antibiotic Guide Table 1: Antibiotic selection options for healthcare associated and/or immunocompromised patients • Healthcare associated: intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, attendance at a hospital or hemodialysis clinic within the prior 30 days • Immunocompromised: Receiving chemotherapy, known systemic cancer not in remission, ANC <500, severe cell-mediated immune deficiency Table 2: Antibiotic selection options for community acquired, immunocompetent patients Table 3: Antibiotic selection options for patients with simple sepsis, community acquired, immunocompetent patients requiring hospitalization. Risk Factors for Select Organisms P. aeruginosa MRSA Invasive Candidiasis VRE (and other resistant GNR) Community acquired: • Known colonization with MDROs • Central venous catheter • Liver transplant • Prior IV antibiotics within 90 day • Recent MRSA infection • Broad-spectrum antibiotics • Known colonization • Known colonization with MDROs • Known MRSA colonization • + 1 of the following risk factors: • Prolonged broad antibacterial • Skin & Skin Structure and/or IV access site: ♦ Parenteral nutrition therapy Hospital acquired: ♦ Purulence ♦ Dialysis • Prolonged profound • Prior IV antibiotics within 90 days ♦ Abscess
    [Show full text]
  • Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives
    Difficult Skin and Soft tissue Infections OHSUErin Bonura, MD, MCR Oregon Health & Science University Objectives • Compare and contrast the epidemiology and clinical presentation of common skin and soft tissue diseases • State the management for skin and soft tissue infections OHSU• Differentiate true infection from infectious disease mimics of the skin Casey Casey is a 2 year old boy who presents with this rash. What is the best treatment? A. Soap and Water B. Ibuprofen, it will self OHSUresolve C. Dicloxacillin D. Mupirocin OHSUImpetigo Impetigo Epidemiology and Treatment OHSU Ellen Ellen is a 54 year old morbidly obese woman with DM, HTN and venous stasis who presented with a painful left leg and fever. She has had 3 episodes in the last 6 months. What do you recommend? A. Cefazolin followed by oral amoxicillin prophylaxis B. Vancomycin – this is likely OHSUMRSA C. Amoxicillin – this is likely erysipelas D. Clindamycin to cover staph and strep cellulitis Impetigo OHSUErysipelas Erysipelas Risk: lymphedema, stasis, obesity, paresis, DM, ETOH OHSURecurrence rate: 30% in 3 yrs Treatment: Penicillin Impetigo Erysipelas OHSUCellulitis Cellulitis • DEEPER than erysipelas • Microbiology: – 6-48hrs post op: think GAS… too early for staph (days in the making)! – Periorbital – Staph, Strep pneumoniae, GAS OHSU– Post Varicella - GAS – Skin popping – Staph + almost anything! Framework for Skin and Soft Tissue Infections (SSTIs) NONPurulent Purulent Necrotizing/Cellulitis/Erysipelas Furuncle/Carbuncle/Abscess Severe Moderate Mild Severe Moderate Mild I&D I&D I&D I&D IV Rx Oral Rx C&S C&S C&S C&S Vanc + Pip-tazo OHSUEmpiric IV Empiric MRSA Oral MRSA TMP/SMX Doxy What Are Your “Go-To” Oral Options For Non-Purulent SSTI? Amoxicillin Doxycycline OHSUCephalexin Doxycycline Trimethoprim-Sulfamethoxazole OHSU Miller LG, et al.
    [Show full text]